Kos Pharmaceuticals To Report First Quarter Results On May 3, 2005 Con

    Business Editors

    CRANBURY, N.J.--(BUSINESS WIRE)--April 8, 2005--Kos Pharmaceuticals, Inc. (Nasdaq:KOSP), a fully integrated specialty pharmaceutical company, will announce results for the first quarter ended March 31, 2005, before the market opens on Tuesday, May 3, 2005.
    Following the release, Kos' senior management will host a conference call at 11:00 a.m. ET to discuss the Company's quarterly results. The conference call will be available live via the Internet by accessing Kos' website at www.kospharm.com. Please go to the website at least fifteen minutes prior to the call to register, download and install any necessary audio software. For those who cannot access the webcast, you can dial into the conference call at 913-981-5545 confirmation code 3413852. A replay will also be available on the website at www.kospharm.com or by calling 719-457-0820 domestic or international, and entering 3413852 from 2:00 PM ET on May 3, 2005 until 12:00 AM ET on Thursday, May 5, 2005.
    If you would like to receive notices and news on Kos, please visit the Investor Relations section of the Company website at www.kospharm.com and subscribe to eMail alerts.

    Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases. The Company's principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, or patient compliance. The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, and Azmacort(R) for the treatment of asthma. Kos is developing additional products and has proprietary drug delivery technologies in solid-dose and aerosol metered-dose inhalation administration and is pursuing certain strategic business development and licensing opportunities.

--30--AS/cg*

CONTACT: Kos Pharmaceuticals, Inc. Constance Bienfait, 954-331-3760 or Yvonne Bulla, 954-331-3833

KEYWORD: NEW JERSEY INDUSTRY KEYWORD: PHARMACEUTICAL EARNINGS CONFERENCE CALLS SOURCE: Kos Pharmaceuticals, Inc.

Copyright Business Wire 2005